Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report

We report the case of a 49-year-old woman with ER+ HER2- metastatic breast cancer who experienced an exceptionally long response to capecitabine administered as second-line therapy following a first-line anthracycline-based chemotherapy. Diagnoses: The patient was diagnosed with ER+ HER2- metastatic breast cancer with massive liver involvement and mediastinal lymph nodes metastasis. Interventions: This patient was treated with capecitabine 1000 mg/mq bid given intermittently for 14 days within a 21-day cycle as a second-line therapy following a rapid progression on letrozole treatment given as a maintenance therapy. Outcomes: Our patient experienced a progression-free survival (PFS)>3 years with an exceptionally good quality of life (QoL). Lessons: In ER+HER2- metastatic breast cancer patients, capecitabine monochemotherapy in second line may be associated with a particularly satisfactory PFS and no impact in terms of QoL. Future studies focused on biomarkers with predictive ability may help select patients who represent the best candidates to this treatment.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research